Bob Li is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 577 publications with 21,634 citations (h-index 60).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1275 York Avenue
Memorial Sloan Kettering Cancer Center
New York, NY 100656800
Telephone
646-888-4201Registry record last updated 16 Mar 2016.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20231 payment
- Daiichi Sankyo Company LTDProgram year20231 payment
- AstraZeneca UK LimitedProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
38.6%Kinase inhibitor28.4%Tagrisso67%Everolimus19%Tabrecta15%Part D<11 patientsEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors6%Vizimpro100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
28.4%Serotonin-3 Receptor Antagonist7.7%Ondansetron Hcl100%Part D≥15 patientsH2 blocker5.6%Famotidine100%Part D<11 patients+ 3 more classes in this area
Nervous system
10.2%Opioid Agonist5.3%Oxycodone Hcl100%Part D<11 patientsBenzodiazepine4.9%Lorazepam100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2023 per NIH RePORTER. The latest:
- HER2-mediated delivery of cytotoxic agents in solid tumors
Sloan-Kettering Inst Can Research
FY2023$576,031R01CA249666 - HER2-mediated delivery of cytotoxic agents in solid tumors
Sloan-Kettering Inst Can Research
FY2022$576,029R01CA249666 - HER2-mediated delivery of cytotoxic agents in solid tumors
Sloan-Kettering Inst Can Research
FY2021$587,787R01CA249666
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”